Debra K. Liebert - Oct 20, 2022 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Role: Director
Signature: /s/ Jason Minio, Attorney-in-Fact
Stock symbol: MIST
Transactions as of: Oct 20, 2022
Transactions value $: $73,940
Form type: 4
Date filed: 10/21/2022, 07:02 PM
Previous filing: Sep 15, 2022
Next filing: Jun 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MIST	Common Shares	Purchase	$52.9K	+10K	$5.29	10K	Oct 20, 2022	By: The Rodriguez and Liebert Revocable Trust	F1
transaction	MIST	Common Shares	Purchase	$21K	+4K	$5.26	4K	Oct 21, 2022	By: Trust	F2
holding	MIST	Common Shares					127	Oct 20, 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.24 to $5.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	These shares are held in a trust for the benefit of several including the Reporting Person's spouse. The Reporting Person's spouse is a co-executor of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.24 to $5.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

These shares are held in a trust for the benefit of several including the Reporting Person's spouse. The Reporting Person's spouse is a co-executor of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.